JP Morgan Cuts Celgene Rating

Analyst Franklin Berger thinks Celgene's drug-trial delay will affect FDA approval -- and thus, sales -- of another up-and-coming treatment

JP Morgan downgraded Celgene Corp. (CELG ) to long-term buy from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.